Who is sponsoring NCT04772352?

NCT04772352 is sponsored by Ningbo No. 1 Hospital.

What drugs are being tested in NCT04772352?

Interventions in NCT04772352: febuxostat treatment, lifestyle intervention.

What condition does NCT04772352 study?

NCT04772352 studies Nonalcoholic Fatty Liver Disease.

Is NCT04772352 still recruiting?

NCT04772352 is currently status unknown. Last updated 26 February 2021.

Last reviewed 2021-02-26 · How we verify

NCT04772352

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout

Status unknown Phase 2 Last updated 26 February 2021

What this trial tests

Phase 2 trial testing febuxostat treatment in Nonalcoholic Fatty Liver Disease in 200 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
1 August 2021

1 March 2022

Quick facts

Lead sponsor	Ningbo No. 1 Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 March 2021
Primary completion	1 August 2021
Estimated completion	1 March 2022
Sites	1 location across China

Drugs / interventions tested

febuxostat treatment — full drug profile →
lifestyle intervention

Conditions studied

Nonalcoholic Fatty Liver Disease — all drugs for Nonalcoholic Fatty Liver Disease →

Sponsor

Ningbo No. 1 Hospital

Who can join

Adults 18 to 65, any sex, with Nonalcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China. It is important to effectively prevent and control NAFLD and its related diseases. Previous studies show the level of serum uric acid is significantly elevated in patients with NAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic target for NAFLD. This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD through a large sample prospective study. Furthermore, this study explore whether Xanthine oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating NAFLD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Nonalcoholic Fatty Liver Disease

Currently open trials in the same condition.

NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
NCT07248371 — Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases · recruiting
NCT07149571 — To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status · recruiting
NCT06368882 — Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty · Phase 4 · recruiting

Other Ningbo No. 1 Hospital trials

Trials by the same sponsor.

NCT07181759 — Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone · NA · not yet recruiting
NCT07001865 — Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia · enrolling by invitation
NCT06984510 — Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population · recruiting
NCT06905795 — Screening and Intervention of MASLD in Children · NA · active not recruiting
NCT06987760 — Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04772352 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ningbo No. 1 Hospital
Last refreshed: 26 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04772352.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing